Übersichtsarbeit
Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics · 2024
DOI: 10.58347/tml.2024.1708c ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2024. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Hypoglycemic Agents, Gastric Inhibitory Polypeptide.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Diabetes Mellitus, Type 2Glucagon-Like Peptide 1Hypoglycemic AgentsGastric Inhibitory PolypeptideGlucagon-Like Peptide-1 Receptor AgonistsHumansReceptors, Gastrointestinal HormoneAnimalsGlucagon-Like Peptide-1 Receptor
Stichwörter der Autor:innen
Bydureon BCiseByettaMounjaroOzempicRybelsusTrulicityVictozaadverse effectsdosagedrug interactionsdulaglutideexenatidelactationliraglutidepregnancy
Substanzen
Glucagon-Like Peptide 1Hypoglycemic AgentsGastric Inhibitory PolypeptideReceptors, Gastrointestinal HormoneGlucagon-Like Peptide-1 Receptor AgonistsGLP1R protein, humanGlucagon-Like Peptide-1 Receptorgastric inhibitory polypeptide receptor
Zitieren
APA
(2024). Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1708c
Vancouver
Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1708c
BibTeX
@article{euvimed2024,
title = {Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2024},
doi = {10.58347/tml.2024.1708c}
}
EUVIMED